Inflammatory lung diseases like COPD and scarring conditions kill neutrophils too slowly, leaving them to damage healthy tissue. Over two decades, this research team has identified a way to force those neutrophils to commit suicide and be cleared silently by scavenger cells called macrophages. The problem is that powerful survival factors in the inflamed lung usually override this suicide process. Now, the team has shown that a cancer drug called R-roscovitine, already in clinical trials, unexpectedly triggers neutrophil suicide even in the presence of those survival factors. In models of human inflammatory lung disease, the drug made the inflammation resolve. The work was published in *Nature Medicine*. This matters because current treatments for these lung diseases are poorly effective, and the conditions cause a huge burden of illness and untimely deaths in the UK. If this research succeeds, it could lead to a new class of anti-inflammatory drugs that work by harnessing the body’s own resolution mechanisms. The team will also run a clinical study using cutting-edge imaging to monitor disease progression non-invasively and demonstrate the drug’s effectiveness in patients.
View original technical description
Inflammatory lung diseases like chronic bronchitis and emphysema (COPD) and scarring conditions are responsible for a huge burden of illness and untimely deaths in the UK, but current treatments are at best poorly-effective. Over the past twenty years we have been taking an alternative approach to harness the mechanisms by which some inflammatory responses are known to get better spontaneously. Specifically we have identified a mechanism by which key inflammatory cells called neutrophils can be made to commit suicide and be removed silently by local scavenger cells called macrophages. Unfortunately this suicide process is usually overcome by powerful survival factors present in the inflamed lung. In work newly-published in the leading international medical science journal Nature Medicine we have shown that a CDK inhibitor called R-roscovitine, currently under clinical trial in cancer patients, causes a hitherto unexpected induction of neutrophil suicide, even in the presence of survival factors, and makes relevant models of human inflammatory lung disease resolve. This work has recently been publicised in the lay press. In our proposed programme of research we will define exactly how this works, an approach which may lead to the discovery of other useful anti-inflammatory drugs. We will also carry out a clinical study of the drug s effectiveness using cutting-edge imaging technology to monitor the progress of the disease non-invasively and demonstrate its response to treatment.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know